Nathan M. Kendsersky

This paper identifies cell state-dependent and -independent immunotherapeutic targets in neuroblastoma by analyzing subtype-specific gene expression and validating targets through experimental methods.

This paper identifies design principles for modifying Hsp104 to enhance its therapeutic potential by tuning its collaboration with Hsp70 and Hsp40.

This study shows BPTF works with MYCN and MYC to control cell cycle and epigenetic states in neuroblastoma, linking it to poor prognosis and therapeutic potential.

The paper provides ChIP-Seq and ATAC-Seq data for MYCN, MYC, and histone marks in neuroblastoma cell lines to study gene regulation and enhancer dynamics.

This paper genomically characterizes 261 pediatric cancer patient-derived xenograft models to guide rational clinical trial design and drug development.